LFST Quote, Financials, Valuation and Earnings

The Ensign Group, Inc. has a net margin of 0.3% compared to Lifestance Health Group, Inc.'s net margin of 6.47%. Lifestance Health Group, Inc.'s return on equity of -0.62% beat The Ensign Group, Inc.'s return on equity of 16.99%.

Lifestance Health Group, Inc. has a consensus price target of $8.56, signalling upside risk potential of 20.67%. On the other hand The Ensign Group, Inc. has an analysts' consensus of $207.20 which suggests that it could grow by 17.29%. Given that Lifestance Health Group, Inc. has higher upside potential than The Ensign Group, Inc., analysts believe Lifestance Health Group, Inc. is more attractive than The Ensign Group, Inc..

Lifestance Health Group, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Ensign Group, Inc. has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.196%.

Lifestance Health Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Ensign Group, Inc. offers a yield of 0.14% to investors and pays a quarterly dividend of $0.06 per share. Lifestance Health Group, Inc. pays -- of its earnings as a dividend. The Ensign Group, Inc. pays out 4.74% of its earnings as a dividend. The Ensign Group, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Lifestance Health Group, Inc. quarterly revenues are $363.8M, which are smaller than The Ensign Group, Inc. quarterly revenues of $1.3B. Lifestance Health Group, Inc.'s net income of $1.1M is lower than The Ensign Group, Inc.'s net income of $83.9M. Notably, Lifestance Health Group, Inc.'s price-to-earnings ratio is -- while The Ensign Group, Inc.'s PE ratio is 31.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifestance Health Group, Inc. is 2.01x versus 2.14x for The Ensign Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Guardian Pharmacy Services, Inc. has a net margin of 0.3% compared to Lifestance Health Group, Inc.'s net margin of 2.54%. Lifestance Health Group, Inc.'s return on equity of -0.62% beat Guardian Pharmacy Services, Inc.'s return on equity of 24.04%.

Lifestance Health Group, Inc. has a consensus price target of $8.56, signalling upside risk potential of 20.67%. On the other hand Guardian Pharmacy Services, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 10.18%. Given that Lifestance Health Group, Inc. has higher upside potential than Guardian Pharmacy Services, Inc., analysts believe Lifestance Health Group, Inc. is more attractive than Guardian Pharmacy Services, Inc..

Lifestance Health Group, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Guardian Pharmacy Services, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lifestance Health Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardian Pharmacy Services, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifestance Health Group, Inc. pays -- of its earnings as a dividend. Guardian Pharmacy Services, Inc. pays out 128.01% of its earnings as a dividend.

Lifestance Health Group, Inc. quarterly revenues are $363.8M, which are smaller than Guardian Pharmacy Services, Inc. quarterly revenues of $377.4M. Lifestance Health Group, Inc.'s net income of $1.1M is lower than Guardian Pharmacy Services, Inc.'s net income of $9.6M. Notably, Lifestance Health Group, Inc.'s price-to-earnings ratio is -- while Guardian Pharmacy Services, Inc.'s PE ratio is 48.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifestance Health Group, Inc. is 2.01x versus 1.40x for Guardian Pharmacy Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PACS Group, Inc. has a net margin of 0.3% compared to Lifestance Health Group, Inc.'s net margin of 3.89%. Lifestance Health Group, Inc.'s return on equity of -0.62% beat PACS Group, Inc.'s return on equity of 21.93%.

Lifestance Health Group, Inc. has a consensus price target of $8.56, signalling upside risk potential of 20.67%. On the other hand PACS Group, Inc. has an analysts' consensus of $42.60 which suggests that it could grow by 14.18%. Given that Lifestance Health Group, Inc. has higher upside potential than PACS Group, Inc., analysts believe Lifestance Health Group, Inc. is more attractive than PACS Group, Inc..

Lifestance Health Group, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PACS Group, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lifestance Health Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PACS Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifestance Health Group, Inc. pays -- of its earnings as a dividend. PACS Group, Inc. pays out -- of its earnings as a dividend.

Lifestance Health Group, Inc. quarterly revenues are $363.8M, which are smaller than PACS Group, Inc. quarterly revenues of $1.3B. Lifestance Health Group, Inc.'s net income of $1.1M is lower than PACS Group, Inc.'s net income of $52.3M. Notably, Lifestance Health Group, Inc.'s price-to-earnings ratio is -- while PACS Group, Inc.'s PE ratio is 35.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifestance Health Group, Inc. is 2.01x versus 1.18x for PACS Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Pennant Group, Inc. has a net margin of 0.3% compared to Lifestance Health Group, Inc.'s net margin of 3.01%. Lifestance Health Group, Inc.'s return on equity of -0.62% beat The Pennant Group, Inc.'s return on equity of 9.98%.

Lifestance Health Group, Inc. has a consensus price target of $8.56, signalling upside risk potential of 20.67%. On the other hand The Pennant Group, Inc. has an analysts' consensus of $36.33 which suggests that it could grow by 24.3%. Given that The Pennant Group, Inc. has higher upside potential than Lifestance Health Group, Inc., analysts believe The Pennant Group, Inc. is more attractive than Lifestance Health Group, Inc..

Lifestance Health Group, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Pennant Group, Inc. has a beta of 1.311, suggesting its more volatile than the S&P 500 by 31.126%.

Lifestance Health Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Pennant Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifestance Health Group, Inc. pays -- of its earnings as a dividend. The Pennant Group, Inc. pays out -- of its earnings as a dividend.

Lifestance Health Group, Inc. quarterly revenues are $363.8M, which are larger than The Pennant Group, Inc. quarterly revenues of $229M. Lifestance Health Group, Inc.'s net income of $1.1M is lower than The Pennant Group, Inc.'s net income of $6.9M. Notably, Lifestance Health Group, Inc.'s price-to-earnings ratio is -- while The Pennant Group, Inc.'s PE ratio is 38.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifestance Health Group, Inc. is 2.01x versus 1.22x for The Pennant Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.